Screening for Lung Cancer

Video Library - Lung Cancer, Video
Edward Garon, MD
Dr. Edward Garon talks about the best approaches for screening patients for lung cancer.
Related Items
CheckMate-227 Meets Co-Primary End Point of PFS with Nivolumab/Ipilimumab Combination in NSCLC, Confirms TMB as Viable Biomarker
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Treatment Paradigm Shift in ALK-Positive NSCLC Raises Further Questions Regarding ALK Inhibitor Sequencing
TON Web Exclusives published on March 16, 2018 in Lung Cancer
FDA Grants Orphan Drug Designation to Seribantumab, an Investigational Treatment for Heregulin-Positive NSCLC
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Three Leading Medical Societies Update Molecular Testing Guideline for Lung Cancer TKI Treatment
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Brigatinib May Prolong Survival After Progression of Crizotinib-Refractory, ALK-Positive NSCLC
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Osimertinib Nearly Doubles PFS, Receives Breakthrough Therapy Designation in Frontline Treatment of EGFR-Positive NSCLC
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Pembrolizumab, Pemetrexed, and Platinum Chemotherapy Combination Shows Improved OS and PFS in Patients with Metastatic Nonsquamous NSCLC
TON Web Exclusives published on February 12, 2018 in Lung Cancer
FDA Approves Alectinib for ALK-Positive, Metastatic Non–Small-Cell Lung Cancer
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Therapeutic Options for Patients with ALK-Positive NSCLC After Disease Progression with Crizotinib
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Next-Generation ALK/ROS1 Inhibitor Lorlatinib Shows Strong, Durable Responses in Advanced NSCLC
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Last modified: April 27, 2017